
## Sze-Yuan Ooi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/917328/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	High Intensity Interval versus Moderate Intensity Continuous Training in Patients with Coronary Artery Disease: A Meta-analysis of Physiological and Clinical Parameters. Heart Lung and Circulation, 2016, 25, 166-174.	0.4	132
2	Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal, 2021, 42, 2630-2642.	2.2	69
3	Detection of Obstructive Coronary Artery Disease Using Peak Systolic Global Longitudinal Strain Derived by Two-Dimensional Speckle-Tracking: A Systematic Review and Meta-Analysis. Journal of the American Society of Echocardiography, 2016, 29, 724-735.e4.	2.8	68
4	Mobile Phone Technologies in the Management of Ischemic Heart Disease, Heart Failure, and Hypertension: Systematic Review and Meta-Analysis. JMIR MHealth and UHealth, 2020, 8, e16695.	3.7	45
5	Impact of Incomplete Percutaneous Revascularization in Patients With Multivessel Coronary Artery Disease: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2016, 5, .	3.7	36
6	Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	27
7	Evaluation of an mHealth-Based Adjunct to Outpatient Cardiac Rehabilitation. IEEE Journal of Biomedical and Health Informatics, 2018, 22, 1938-1948.	6.3	27
8	A Smartphone-Based Model of Care to Support Patients With Cardiac Disease Transitioning From Hospital to the Community (TeleClinical Care): Pilot Randomized Controlled Trial. JMIR MHealth and UHealth, 2022, 10, e32554.	3.7	27
9	Recommendation to Use Wearable-Based mHealth in Closed-Loop Management of Acute Cardiovascular Disease Patients During the COVID-19 Pandemic. IEEE Journal of Biomedical and Health Informatics, 2021, 25, 903-908.	6.3	24
10	Prognostic Significance of Peri-procedural Myocardial Infarction in the Era of High Sensitivity Troponin: A Validation of the Joint ACCF/AHA/ESC/WHF Universal Definition of Type 4a Myocardial Infarction with High Sensitivity Troponin T. Heart Lung and Circulation, 2015, 24, 673-681.	0.4	21
11	Heart-type fatty acid binding protein in early diagnosis of myocardial infarction in the era of high-sensitivity troponin: a systematic review and meta-analysis. Annals of Clinical Biochemistry, 2015, 52, 370-381.	1.6	18
12	Automated segmentation of normal and diseased coronary arteries – The ASOCA challenge. Computerized Medical Imaging and Graphics, 2022, 97, 102049.	5.8	18
13	Drug-eluting Balloon Versus Second Generation Drug Eluting Stents in the Treatment of In-stent Restenosis: A Systematic Review and Meta-analysis. Heart Lung and Circulation, 2016, 25, 1184-1194.	0.4	17
14	BioMonitor 2 Pilot Study: Early Experience With Implantation of the Biotronik BioMonitor 2 Implantable Cardiac Monitor. Heart Lung and Circulation, 2018, 27, 1462-1466.	0.4	15
15	Scedosporium apiospermum pacemaker endocarditis. International Journal of Cardiology, 2009, 131, e81-e82.	1.7	14
16	Ankyrin-B Syndrome: A Case of Sinus Node Dysfunction, Atrial Fibrillation and Prolonged QT in a Young Adult. Heart Lung and Circulation, 2015, 24, e31-e34.	0.4	14
17	Cardiac And Vascular Responses In Deoxycorticosterone Acetate-Salt Hypertensive Rats. Clinical and Experimental Pharmacology and Physiology, 2000, 27, 263-269.	1.9	9
18	Optimal duration of dual antiplatelet therapy following drug-eluting stents implantation: A meta-analysis of 7 randomised controlled trials. International Journal of Cardiology, 2015, 201, 578-580.	1.7	8

SZE-YUAN OOI

#	Article	IF	CITATIONS
19	Twelve-Month Outcomes With a Bioresorbable Everolimus-Eluting Scaffold: Results of the ESHC-BVS Registry at Two Australian Centers. Journal of Invasive Cardiology, 2016, 28, 316-22.	0.4	8
20	ACE inhibitors: their propertiesand current role in hypertension. The Prescriber, 2009, 20, 15-28.	0.3	7
21	Design and Rationale for the Endothelin-1 Receptor Antagonism in the Prevention of Microvascular Injury in Patients with non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (ENDORA-PCI) Trial. Cardiovascular Drugs and Therapy, 2016, 30, 169-175.	2.6	6
22	Trials and Tribulations: mHealth Clinical Trials in the COVID-19 Pandemic. Yearbook of Medical Informatics, 2021, 30, 272-279.	1.0	6
23	Burden of cardiovascular diseases in older adults using aged care services. Age and Ageing, 2021, 50, 1845-1849.	1.6	6
24	ACE inhibitors: their properties and role in hypertension. The Prescriber, 2007, 18, 48-61.	0.3	5
25	Is There Attenuation of Benefit of Invasive Therapy in Patients with Chronic Kidney Disease? Results from Randomized Trials and Registry Data. Current Cardiology Reports, 2012, 14, 521-527.	2.9	4
26	Process Evaluation of a Randomised Controlled Trial for TeleClinical Care, a Smartphone-App Based Model of Care. Frontiers in Medicine, 2021, 8, 780882.	2.6	4
27	Peri-procedural myocardial infarction following percutaneous coronary intervention as defined by the Universal Definition predicts increased mortality at 2years. International Journal of Cardiology, 2015, 199, 96-98.	1.7	3
28	A new and automated risk prediction of coronary artery disease using clinical endpoints and medical imaging-derived patient-specific insights: protocol for the retrospective GeoCAD cohort study. BMJ Open, 2022, 12, e054881.	1.9	2
29	Statins and rheumatoid arthritis. Lancet, The, 2004, 364, 1853-1854.	13.7	1
30	Reply: High Intensity Interval versus Moderate Intensity Continuous Training in Patients with Coronary Artery Disease. Heart Lung and Circulation, 2017, 26, 528-529.	0.4	1
31	Resting Full-Cycle Ratio (RFR) in the Assessment of Left Main Coronary Disease: Caution Required. Heart Lung and Circulation, 2020, 29, 1256-1259.	0.4	1

Telemedicine systems to manage chronic disease. , 2021, , 177-195.

0